Menogaril in the treatment of relapsed multiple myeloma. A phase II trial of the Cancer Center of Wake Forest University.
Fifteen patients with relapsed multiple myeloma (MM) were treated with menogaril 160 mg/m2 intravenously (IV) every 28 days. No responses were seen: 8 patients had stable disease, 4 progressed after one course of therapy, and 3 patients were removed from study after 1 course for other reasons. Four of the 8 patients with stable disease had an improved performance status, and 3 had a decrease in analgesic use. The major toxicity was myelosuppression. The median progression-free interval was 3.0 months with a range of 0.7 to 22 months and median survival was 11.3 months with a range of 0.7 to 39+ months. Menogaril displays little activity in patients with previously treated MM.
Cruz
J M
JM
Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC.
Case
L D
LD
Dalton
H B
HB
Ramseur
W L
WL
Richards
F
F
Jackson
D V
DV
Muss
H B
HB
Zekan
P J
PJ
Brodkin
R A
RA
Brown
R C
RC
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D006801:Humans; D017290:Menogaril; D009101:Multiple Myeloma / Q000188:drug therapy*; D009621:Nogalamycin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*
D000970:Antineoplastic Agents; D017290:Menogaril; D009621:Nogalamycin